Johnson & Johnson (NYSE:JNJ) decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa ...

A DMT-based treatment for people with treatment-resistant depression (TRD) has entered Phase 2 clinical trials.

J&J is already seeing strong sales growth for its treatment-resistant depression (TRD) and MDD therapy Spravato (esketamine), ...

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...

Johnson & Johnson's Spravato therapy for treatment ... the drugmaker added to the evidence behind Spravato – an intranasal formulation of esketamine – with the release of top-line data from ...

Johnson & Johnson (JNJ) stock in focus as company halts Phase 3 depression therapy trials for aticaprant over efficacy ...

After I have presented the key tasks I faced when creating "ALLKA 4D Rating", I will move on to comparing Johnson & Johnson and Pfizer and choose the winner in the category "the most promising ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...

Johnson & Johnson has added to the opioid kappa blues. Months after Neumora reported a phase 3 flop, J&J has stopped ...

Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...

House Speaker Mike Johnson addressed the “shameful” behavior several Democratic lawmakers showcased at President Donald Trump’s address to Congress, during which these lawmakers “missed ...